Paragon Capital Management Inc Dexcom Inc Transaction History

Paragon Capital Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Sep 26, 2024	SELL	$86.06 - $137.93 $500,094 - $801,511	-5,811 Closed	0 $0
Q2 2023 Sep 26, 2024	SELL	$112.47 - $130.98 $456,290 - $531,385	-4,057 Reduced 41.11%	5,811 $747 Million
Q1 2023 Sep 26, 2024	BUY	$104.0 - $122.92 $523,640 - $618,902	5,035 Added 104.18%	9,868 $1.15 Billion
Q4 2022 Sep 25, 2024	BUY	$84.98 - $122.67 $410,708 - $592,864	4,833 New	4,833 $547 Million
Q2 2022 Sep 25, 2024	SELL	$67.99 - $132.89 $120,614 - $235,746	-1,774 Closed	0 $0
Q1 2022 Sep 25, 2024	SELL	$94.08 - $130.2 $67,267 - $93,092	-715 Reduced 28.73%	1,774 $908 Million
Q4 2021 Sep 25, 2024	BUY	$129.87 - $162.82 $323,246 - $405,258	2,489 New	2,489 $1.34 Billion

1,023

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $34.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Paragon Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Paragon Capital Management Inc with notifications on news.